Cellectis (NASDAQ:CLLS) gapped down prior to trading on Friday . The stock had previously closed at $26.31, but opened at $29.00. Cellectis shares last traded at $29.21, with a volume of 513521 shares.
Several equities research analysts recently issued reports on the company. BidaskClub raised Cellectis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 17th. ValuEngine raised Cellectis from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Zacks Investment Research downgraded Cellectis from a “hold” rating to a “sell” rating in a research note on Wednesday, February 14th. Guggenheim assumed coverage on Cellectis in a research note on Friday, March 16th. They issued a “neutral” rating for the company. Finally, Nomura increased their price objective on Cellectis to $73.00 and gave the stock a “buy” rating in a research note on Wednesday, March 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $42.67.
The stock has a market capitalization of $1,041.92, a price-to-earnings ratio of -10.37 and a beta of 1.86.
Cellectis (NASDAQ:CLLS) last issued its earnings results on Monday, March 12th. The biotechnology company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.12). Cellectis had a negative return on equity of 35.63% and a negative net margin of 298.01%. The firm had revenue of $6.91 million during the quarter, compared to analyst estimates of $10.10 million. analysts expect that Cellectis will post -2.62 EPS for the current fiscal year.
Hedge funds have recently modified their holdings of the business. Perceptive Advisors LLC acquired a new position in shares of Cellectis during the 4th quarter valued at about $10,203,000. BlackRock Inc. acquired a new position in Cellectis during the fourth quarter worth about $4,422,000. Millennium Management LLC boosted its position in Cellectis by 1,356.2% during the fourth quarter. Millennium Management LLC now owns 104,290 shares of the biotechnology company’s stock worth $3,040,000 after acquiring an additional 97,128 shares during the last quarter. Bain Capital Public Equity Management LLC acquired a new position in Cellectis during the fourth quarter worth about $2,848,000. Finally, Granite Point Capital Management L.P. acquired a new position in Cellectis during the fourth quarter worth about $1,458,000. 20.31% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Cellectis (CLLS) Shares Gap Down to $29.00” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/08/cellectis-clls-shares-gap-down-to-29-00.html.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.